S2Medical Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Petter Sivlér

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.8yrs
CEO sahipliği	0.001%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Petter Sivlér (39 yo)

11.8yrs

Görev süresi

Mr. Petter Sivlér Co-Founded S2Medical AB (publ) and has been its Chief Executive Officer from 2013.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mårten Skog	Co-Founder	11.8yrs	Veri yok	Veri yok
Fredrik Skog	Chair of the Board	2.9yrs	Veri yok	0.0094% € 23.6
Miles Wright	Director	2.9yrs	Veri yok	Veri yok
Chadi Asaad	Director	2.9yrs	Veri yok	Veri yok
Patrick Sheehan	Director	2.9yrs	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: S21 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

S2Medical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

No independent directors

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

No independent directors

Recent updates

New major risk - Revenue size

Second quarter 2024 earnings released

First quarter 2024 earnings released

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: kr0.082 loss per share (vs kr1.24 loss in FY 2022)

New major risk - Shareholder dilution

Third quarter 2023 earnings released

Second quarter 2023 earnings released

S2Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr1.15 loss per share (vs kr1.35 loss in FY 2021)

S2Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

S2Medical AB (publ) Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria

No independent directors

Third quarter 2022 earnings released

EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology

S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia

S2Medical AB (publ) Updates Instagraft-Patent Approval in Israel

S2Medical AB (publ) Receives the Response from the European Patent Office That They Intend to Grant Patent Protection for the Company's Instagraft Technology Within Around Forty European Countries

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released

First quarter 2021 earnings released

New 90-day low: €0.69

New 90-day low: €0.76

S2Medical AB (publ) (OM:S2M) entered into an agreement to acquire Curenc AB.

New 90-day high: €0.90

Earnings released

New 90-day high - €0.86

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi